-
公开(公告)号：US20190161448A1
公开(公告)日：2019-05-30
申请号：US16096710
申请日：2017-05-19
Applicant: Merck Sharp & Dohme Corp.
Inventor： Gregory L. Adams , Jason M. Cox , John S. Debenham , Scott Edmondson , Eric J. Gilbert , Yan Guo , Yu Jiang , Hubert Josien , Hyunjin M. Kim , Ping Lan , Shouwu Miao , Christopher W. Plummer , Murali Rajagopalan , Unmesh Shah , Zhongxiang Sun , Quang T. Truong , Feroze Ujjainwalla , Francisco Velazquez , Srikanth Venkatraman , Takao Suzuki , Nengxue Wang
IPC: C07D217/04 , C07D401/12 , C07D401/04 , C07D401/06 , C07D417/04 , C07D417/14 , C07D417/12 , C07D413/04 , A61P3/10 , A61P3/06 , A61P3/04 , A61P29/00
Abstract: The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
-
2.发明授权Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment 有权取代的环丙基化合物，含有这些化合物的组合物和处理方法公开(公告)号：US09422266B2
公开(公告)日：2016-08-23
申请号：US14347268
申请日：2012-09-24
Applicant: Merck Sharp & Dohme Corp.
Inventor： Michael W. Miller , Andrew W. Stamford , Kallol Basu , Scott Edmondson , Zhiqiang Guo , William B. Geiss
IPC: C07D401/12 , C07D401/14 , C07D211/96
CPC classification number: C07D401/12 , C07D211/96 , C07D401/14
Abstract: Substituted cyclopropyl compounds of the formula I and the pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the g-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included. Another aspect of the invention that is of interest relates to compounds of formula 1a.
Abstract translation: 公开了取代的式I的环丙基化合物及其药学上可接受的盐，用于治疗或预防2型糖尿病和类似病状。 该化合物可用作g-蛋白偶联受体GPR-119的激动剂。 还包括药物组合物和治疗方法。 感兴趣的本发明的另一方面涉及式1a的化合物。
-
公开(公告)号：US09018224B2
公开(公告)日：2015-04-28
申请号：US14358241
申请日：2012-11-09
Applicant: Merck Sharp & Dohme Corp.
Inventor： Scott Edmondson , Zhiyong Hu , Ping Liu , Gregori J. Morriello , Jason W. Szewczyk , Bowei Wang , Liping Wang , Harold B. Wood , Cheng Zhu , Yuping Zhu , Zhiqiang Guo
IPC: A01N43/54 , A61K31/505 , C07D513/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D401/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D239/42 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12
CPC classification number: C07D513/04 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
Abstract: Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.
Abstract translation: 披露式（I）的取代的环丙基化合物及其药学上可接受的盐可用于治疗或预防2型糖尿病和类似病状。 该化合物可用作G蛋白偶联受体GPR-119的激动剂。 还包括药物组合物和治疗方法。
-
公开(公告)号：US20200347020A1
公开(公告)日：2020-11-05
申请号：US16935565
申请日：2020-07-22
Applicant: Merck Sharp & Dohme Corp.
Inventor： Gregory L. Adams , Jason M. Cox , John S. Debenham , Scott Edmondson , Eric J. Gilbert , Yan Guo , Yu Jiang , Hubert Josien , Hyunjin M. Kim , Ping Lan , Shouwu Miao , Christopher W. Plummer , Murali Rajagopalan , Unmesh Shah , Zhongxiang Sun , Quang T. Truong , Feroze Ujjainwalla , Francisco Velazquez , Srikanth Venkatraman , Takao Suzuki , Nengxue Wang
IPC: C07D217/04 , C07D401/04 , C07D401/12 , C07D413/04 , C07D417/12 , C07D417/14 , C07D401/06 , C07D417/04 , A61K31/4725 , C07D417/06 , C07D217/22 , A61K45/06 , A61K31/472 , A61K9/48 , A61P3/04 , A61P3/06 , A61P3/10 , A61P29/00
Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
-
Patent Agency Ranking
公开(公告)号：US20140329798A1
公开(公告)日：2014-11-06
申请号：US14358241
申请日：2012-11-09
Applicant: Merck Sharp & Dohme Corp.
Inventor： Scott Edmondson , Zhiyong Hu , Ping Liu , Gregori J. Morriello , Jason W. Szewczyk , Bowei Wang , Liping Wang , Harold B. Wood , Cheng Zhu , Yuping Zhu , Zhiqiang Guo
IPC: C07D513/04 , C07D239/42 , C07D405/12 , C07D409/12 , C07D498/04 , C07D487/04 , C07D403/14 , C07D401/14 , C07D403/12 , C07D471/04
CPC classification number: C07D513/04 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
Abstract: Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included
Abstract translation: 披露式（I）的取代的环丙基化合物及其药学上可接受的盐可用于治疗或预防2型糖尿病和类似病状。 该化合物可用作G蛋白偶联受体GPR-119的激动剂。 还包括药物组合物和治疗方法
-
公开(公告)号：US11161819B2
公开(公告)日：2021-11-02
申请号：US16935565
申请日：2020-07-22
Applicant: Merck Sharp & Dohme Corp.
Inventor： Gregory L. Adams , Jason M. Cox , John S. Debenham , Scott Edmondson , Eric J. Gilbert , Yan Guo , Yu Jiang , Hubert Josien , Hyunjin M. Kim , Ping Lan , Shouwu Miao , Christopher W. Plummer , Murali Rajagopalan , Unmesh Shah , Zhongxiang Sun , Quang T. Truong , Feroze Ujjainwalla , Francisco Velazquez , Srikanth Venkatraman , Takao Suzuki , Nengxue Wang
IPC: C07D217/04 , C07D401/04 , C07D401/12 , C07D413/04 , C07D417/12 , C07D417/14 , C07D401/06 , C07D417/04 , A61K31/4725 , C07D417/06 , C07D217/22 , A61K45/06 , A61K31/472 , A61K9/48 , A61P3/04 , A61P3/06 , A61P3/10 , A61P29/00
Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
-
公开(公告)号：US09809545B2
公开(公告)日：2017-11-07
申请号：US14778765
申请日：2014-03-21
Applicant: Merck Sharp & Dohme Corp.
Inventor： Anthony Ogawa , Scott Edmondson , Mark Erion , Santhosh Neelamkavil , Zhuyan Guo , Rudrajit Mal , Jiafang He , Weiguo Liu , Ellen K. Vande Bunte
IPC: C07D401/14 , C07D213/64 , A61K31/551 , C07D401/04 , C07D405/14 , C07D413/14 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/12 , C07D413/06 , C07D413/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/044 , C07D491/052 , C07F9/6558
CPC classification number: C07D213/64 , A61K31/551 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/044 , C07D491/052 , C07F9/65583
Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.
-
公开(公告)号：US20160046581A1
公开(公告)日：2016-02-18
申请号：US14778765
申请日：2014-03-21
Applicant: Anthony OGAWA , Scott EDMONDSON , Mark ERION , Santosh NEELAMKAVIL , Zhuyan GUO , Rudrajit MAL , Jiafang HE , Weiguo LIU , Ellen K. VAN BUNTE , MERCK SHARP & DOHME CORP.
Inventor： Anthony Ogawa , Scott Edmondson , Mark Erion , Santhosh Neelamkavil , Zhuyan Guo , Rudrajit Mal , Jiafang He , Weiguo Liu , Ellen K. Vande Bunte
IPC: C07D213/64 , C07D401/14 , C07F9/6558 , C07D487/04 , C07D413/06 , C07D491/052 , C07D401/12 , C07D401/10 , C07D413/14
CPC classification number: C07D213/64 , A61K31/551 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/044 , C07D491/052 , C07F9/65583
Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.
Abstract translation: 本发明提供式（I）的化合物和包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓形成，栓塞，高凝状态或纤维变化的方法。
-
9.发明申请SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT 有权取代的环丙基化合物，包含这些化合物的组合物和处理方法公开(公告)号：US20140256699A1
公开(公告)日：2014-09-11
申请号：US14347268
申请日：2012-09-24
Applicant: Merck Sharp & Dohme Corp.
Inventor： Michael W. Miller , Andrew W. Stamford , Kallol Basu , Scott Edmondson , Zhiqiang Guo , William B. Geiss
IPC: C07D401/14 , C07D401/12
CPC classification number: C07D401/12 , C07D211/96 , C07D401/14
Abstract: Substituted cyclopropyl compounds of the formula I and the pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the g-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included. Another aspect of the invention that is of interest relates to compounds of formula Ia.
Abstract translation: 公开了取代的式I的环丙基化合物及其药学上可接受的盐，用于治疗或预防2型糖尿病和类似病状。 该化合物可用作g-蛋白偶联受体GPR-119的激动剂。 还包括药物组合物和治疗方法。 感兴趣的本发明的另一方面涉及式Ia化合物。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.021 seconds)
